Starkey, in collaboration with MED-EL, has introduced DualSync, a bimodal streaming partnership enabling Apple technology to seamlessly stream to compatible Starkey hearing aids and MED-EL cochlear implants.
Beginning July 1, Starkey Genesis AI and Edge AI hearing aids and MED-EL Sonnet 3, Sonnet 2, Sonnet, and Rondo 3 audio processors are compatible for bimodal streaming. People who use both hearing aid and cochlear implant technology will now be able to stream between the two devices for a Bluetooth listening experience.
DualSync is designed to support a growing ecosystem of devices and will be compatible with future innovations from both companies. According to a press release, DualSync technology provides seamless audio connectivity and synchronized sound from compatible smartphones and media devices.
“Hearing loss takes many forms and, in some cases, multiple technologies are required for the best outcome of the patient,” said Brandon Sawalich, president and CEO of Starkey. “Today, two global tech leaders are combining world-class innovations to connect more people back to the things they love most. Partnering with MED-EL reflects our shared commitment to delivering excellence without exception.”
“By uniting two leading technologies, we are delivering a global solution that gives bimodal users effortless connectivity, clearer sound, and greater control in their daily lives,” adds Dr. Ingeborg Hochmair, co-founder and CEO of MED-EL. “Our shared goal is simple: to make it easier for people everywhere to hear, communicate, and engage with the world – using the most advanced technology available.”
Starkey is a privately held global hearing technology company headquartered in Eden Prairie. The company has more than 5,000 employees, operates 29 facilities, and does business in more than 100 markets worldwide. It is the only American-owned provider of hearing technologies.
Comments
We offer several ways for our readers to provide feedback. Your comments are welcome on our social media posts (Facebook, X, Instagram, Threads, and LinkedIn). We also encourage Letters to the Editor; submission guidelines can be found on our Contact Us page. If you believe this story has an error or you would like to get in touch with the author, please connect with us.